CID-16020046 is a compound which acts as an inverse agonist at the former orphan receptor GPR55, and may be the first selective inverse agonist characterised for this receptor. It was found to block a number of GPR55 mediated responses such as wound healing and activation of immune system T-cells and B-cells, as well as showing inverse agonist activity in the absence of GPR55 agonist stimulation. However while it was found to have good selectivity over the related CB1 and CB2 cannabinoid receptors as well as a number of other targets, CID-16020046 has not yet been tested against another related receptor GPR18, so its selectivity for GPR55 over this target has not been established.
- ^ Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M, Heinemann A. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. Journal of Pharmacology and Experimental Therapeutics. 2013 Jul;346(1):54-66. DOI 10.1124/jpet.113.204180. PMID 23639801
- Note: The above list contains only some known CB1R agonists, as too many exist to list here completely. Refer here instead for more.
- Agonists: 2-AG
- 2-AGE (noladin ether)
- GW-405,833 (L-768,242)
- JTE 7-31
- Serinolamide A
- THC (dronabinol)